What is the mechanism of action for Rystiggo?

Rystiggo (rozanolixizumab-noli) is a neonatal Fc receptor blocker. It’s a monoclonal antibody that may be used to treat an autoimmune disorder called generalized myasthenia gravis.

Rystiggo works by targeting a protein called neonatal Fc receptor (FcRn). By blocking FcRn, Rystiggo prevents autoantibodies from attaching to it instead. When autoantibodies attach to FcRn, they are recycled into the body instead of getting broken down. Too many autoantibodies can worsen MS symptoms by interfering with signaling between nerves and muscles. Rystiggo ensures harmful autoantibodies are broken down normally in cells.